// App-Quantinova.ai

: Compound Application of Thalidomide and Recombinant Human Interferon-α-1b, Interleukin-2 in Different Disease Status of Acute Myeloid Leukemia a Multi-Center Prospective Study of a New Combination of Old Drugs

Researchers

Presenter

  • Lin Chen

Principal Investigators

  • Ruihua Mi

  • Xudong Wei

  • Qingsong Ying

  • Fangfang Yuan

  • Lijie Liang

  • Mengjuan Li

  • Delong Liu

  • Yongping Song

Medical Centers

  • Tumor Hospital of Zhengzhou University/Henan Cancer Hospital, zhengzhou, China

  • New York Medical College, Hawthorne, NY

Locations

  • China

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Acute myelocytic leukemia

  • Deep vein thrombosis

  • Venous thrombosis

Biomarkers

  • Alpha-1-microglobulin/bikunin precursor

  • Interleukin-2

Drug/Treatment

  • Interferon alpha

  • Thalidomide

  • Interleukin

  • Interferon

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved